Welcome to the American College of Toxicology s Webinar Series
|
|
- Victor Fitzgerald
- 6 years ago
- Views:
Transcription
1 Welcome to the American College of Toxicology s Webinar Series
2 Thank You to Our Co-sponsors British Toxicology Society Society of Toxicologic Pathology
3 Drug Metabolite(s) Safety Tes>ng Fred Alavi, Ph.D. The Division of Metabolism and Endocrinology Products United States Food and Drug Administra>on Disclaimer: Views expressed here are those of the author and not the FDA.
4 Metabolite Safety Tes>ng Objec>ves of this webinar Describe what a dispropor;onal or unique human metabolite is in safety tes;ng Determine the value of safety tes;ng of metabolites Iden;fy when it s necessary to characterize metabolites Define the type of metabolite safety studies that may be needed Define the excep;ons to the rules Slide 4
5 Regulatory Guidance Background Evolu;on of regulatory guidelines: Historical approach- - case by case evalua;on DruSafe subcommihee mee;ng (2000) PhRMA MIST posi;on paper (Baillie et al, 2002) FDA Guidance for Industry: Safety Tes;ng of Drug Metabolites (2008) ICH- M3(R2): Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceu;cals (2010, supersedes 2008 FDA guidance) ICH- M3 (R2) Q&A sec;on on metabolites (2013) hhp:// GuidanceComplianceRegulatoryInforma;on/Guidances/default.htm Slide 5
6 Dispropor>onal and Unique Metabolites Defini>on Dispropor;onal human metabolite: Exposure substan;ally ( 2x) higher in humans than in animals Unique human metabolite: Only observed in humans Slide 6
7 Why do safety tes>ng of the metabolites Historically, toxicological and toxicokine;c evalua;ons have focused on ac;ve pharmaceu;cal ingredient (API) due in part to insensi;ve analy;cal methods and contribu;on of metabolites to overall drug toxicity Metabolites across species are o`en similar and require no independent toxicity tes;ng (reason not to do tes;ng) High doses in animals generally cover exposure levels to dispropor;onal human metabolites (reason not to do further tes;ng) Pre- Guidance Metabolite Safety Tes;ng case by case Slide 7
8 Why do safety tes>ng of the metabolites Parent and metabolites contribute to target organ toxicity Differences in the metabolite exposure can result in different toxicity profile. Delayed characteriza;on of dispropor;onal human metabolite may increase safety risk and delay drug registra;on New technologies (HPLC/MS/MS) permit early and accurate characteriza;on of metabolites Differences in drug metabolizing enzymes across species Slide 8
9 Species Differences in CYP450 enzymes P450 Human Mouse Rat Dog Monkey CYP1A2 X X X X X CYP2B6 X CYP2C9 X (12%)* X CYP2C19 X CYP2D6 X (31%)* CYP2E1 X X X X X CYP3A4 X (50%)* * Percentage of drugs metabolized by each CYP enzyme in humans Mar;goni, 2006 Guengerich, 1997 Slide 9
10 Why do safety tes>ng of the metabolites Phase I human metabolites are more likely to pose a safety risk than phase II metabolites (i.e. glucuronide, glutathione conjugates) Pharmacologically ac;ve metabolite may contribute to overall drug pharmacology and toxicity Pharmacologically inac;ve metabolites are not devoid of toxicity thus require toxicological assessment Slide 10
11 Timing of the Drug Metabolite Characteriza>on Slide 11
12 Characterizing Metabolites- - Timing In vitro profiling in test animals and humans before first dose in human study In vitro studies may not concur with in vivo metabolite profile In vivo metabolite characteriza;on in humans prior to large scale clinical trials Compare in vivo metabolite profiles across species Steady state metabolite exposure is required when nonclinical data suggest metabolite/drug accumula;on Single dose radiolabeled study may be used to extrapolate to steady state exposure Slide 12
13 Human Metabolite Decision Chart Slide 13
14 Metabolite exposure greater than 10% of total drug exposure will need further considera>on: q Dispropor;onal human metabolite exposure is less than 2x the animal exposure q Dispropor;onal human metabolite exposure is 2 x animal exposure q Metabolite exposure only seen in humans Slide 14
15 Dispropor>onal Human Metabolite: Factors to consider: Any known toxicity risk Poten;al for genotoxicity Extent of human exposure compared to test species Does the metabolite accumulate with repeated dosing? Reliability and valida;on of the analy;cal assay Synthesis of the metabolite Alternate animal model Background knowledge of the drug class Slide 15
16 Unique Human Metabolites Factors to consider: Extent of human exposure Single dose vs. mul;ple dose exposure Knowledge of the metabolic pathway Biliary exposure in animals Alternate animal model Any new adverse clinical signal Genotoxicity poten;al Slide 16
17 Unique Animal Metabolites Occasionally animals may form a metabolite(s) not detected in humans that may cause toxicity in animals, not relevant to humans. Consider Number of species the metabolite is formed Alternate animal model Iden;fica;on of the metabolic pathway in animals is necessary to exclude toxicity signal relevant to humans Slide 17
18 Points to consider before tes>ng Metabolite is pharmacologically ac;ve or inac;ve Metabolite is unique or dispropor;onal In vitro verses in vivo metabolite profile For drug doses <10 mg/day, greater frac;on of the drug related material might be more appropriate trigger for tes;ng Is metabolite a phase I or phase II product Phase II products- generally less toxic, more water soluble (glucuronide and gluthathione, metabolites with hydroxyl group) vs. more toxic reac;ve acyl glucuronide metabolites Slide 18
19 Nonclinical Studies to Assess the Safety of Dispropor>onal / Unique Human Metabolites Slide 19
20 Nonclinical Studies with Human Metabolite Safety pharmacology studies are not needed unless a new signal iden;fied in humans, not observed in animals Genotoxicity- ü In silico QSAR (Quan;ta;ve Structural- Ac;vity Rela;onship) assessment ü In vivo micronucleus or relevant genotox test General toxicity study in single relevant species (4 to 13 weeks) Embryofetal development study in single relevant species (rat or rabbit) Slide 20
21 Nonclinical Studies with the Human Metabolite Carcinogenicity study in mouse or rat ü Metabolite may be added to parent drug ü Metabolite exposure in carcinogenicity study should provide at least 50% of the exposure seen in humans ü Use of transgenic animal model may be acceptable for carcinogenicity assessment of human metabolite Slide 21
22 Possible Excep>ons to the Rules Some safety tes;ng of metabolites for drugs for life threatening diseases may be waived The 10% rule may not apply for drugs that are extensively metabolized with minimal parent drug exposure The 10% rule may not apply for metabolites with genotoxicity poten;al Metabolites of the phase II metabolism may exceed the 10% rule (i.e. glucuronide metabolites) Previous experience and suppor;ve data for some phase I metabolites may not require rigorous tes;ng (case by case basis) Slide 22
23 Possible Excep>ons to the Rules Embryofetal development study for dispropor;onal metabolite may not be necessary for teratogenic parent drug Jus;fied scien;fically supported data may be used to wave/reduce metabolite safety tes;ng (i.e. similar to parent drug, low overall exposure, metabolites from similar drug class) Slide 23
24 Slide 24
25 A Case Example: Phase II Human Metabolite Early in vitro metabolism profile found metabolism among species to be qualita;vely and quan;ta;vely similar In vivo studies found two dispropor;onally high glucuronide metabolites in humans with minimal or no exposure in animals. In vivo human metabolites were iden;fied as o- glucuronide metabolites, rapidly filtered by the kidney. Ac>on: No further nonclinical assessment was deemed necessary Slide 25
26 A Case Example: Phase I and II metabolites 2 Dispropor;onal (Phase I and II) human metabolites iden;fied Phase I accounted for more than ½ of total drug exposure in plasma Phase II metabolite was not considered a safety risk Ac>on: Clinical study was terminated un;l clarifica;on of the metabolite safety Nonclinical assessment of the Phase I metabolite was ini;ated (genotoxicity, standard toxicology, embryofetal development study..) Slide 26
27 A Case Example: Inac>ve Human Metabolites In vitro: 2 primary hydroxylated (M1, M2) and 2 secondary oxida;ve metabolite (M3, M4) in humans, monkeys, dogs, rats and mice In vivo: no notable M4 exposure in rats or mice In vivo: monkey M4 exposure 1/3 of parent with new toxicity signal (~60% of the human exposure) In vivo: human M4 exposure 4x the parent drug Ac>on: In vitro genotoxicity with M4 (M4 was genotoxic) Toxicology studies in rats with M4 Embryofetal development study in rat with M4 Carcinogenicity assessment of the M4 Slide 27
28 Summary The unique or dispropor;onal human metabolites are rela;vely rare. In vitro profiling of drug metabolites should be conducted before first dose in humans In vivo profiling of metabolites should be resolved before large scale clinical trials. Safety tes;ng of drugs with unique/dispropor;onally higher human metabolites exceeding the 10% the total drug- related product exposure need to be addressed. Overall, early human metabolite characteriza;on can lead to quicker resolu;on of metabolite safety issues. Slide 28
29 References Baillie T, et al. Drug metabolites in safety tes;ng. Toxicol Appl Pharmacol Aug 1;182(3): Robison TW and Jacobs A, Metabolites in safety tes;ng. Bioanalysis Oct;1(7): Gao H, et al. Mee;ng report: metabolites in safety tes;ng (MIST) symposium- safety assessment of human metabolites: what's REALLY necessary to ascertain exposure coverage in safety tests? AAPS J Oct;15(4):970-3 Mar;goni, Groothuis and de Kanter. Species differences between mouse, rat, dog, monkey and human CYP- mediated drug metabolism, inhibi;on and induc;on Expert Opin Drug Metab Toxicol. 2006, 2: Guengerich FP. Comparisons of cataly;c selec;vity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact Oct 24;106(3): Davis- Bruno K and Atrakchi A. regulatory perspec;ve on issues and approaches in characterizing human metabolites. Chem Res Toxicol Dec;19(12): Frederick CB and Obach RS. Metabolites in Safety Tes;ng: MIST for the Clinical Pharmacologist. Transla;onal Medicine (Nature), 2010 Mar; 87(3) Regan et al. Acyl glucuronides: the good, the bad and the ugly. Biopharm Drug Dispos Oct;31(7): US FDA Guidance for Industry: Safety Tes;ng of Drug Metabolites, 2008 ICH- M3(R2): Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceu;cals 2010 ICH- M3(R2) Q&A (R2), Nonclinical Safety Studies for the Conduct of Human Clinical Trials, 2013 hhp:// Slide 29
30 Thank you for your participation in the American College of Toxicology Webinar! We hope to see you at the 35th Annual Meeting of the American College of Toxicology Slide 30
ICH S9 guideline on nonclinical evaluation for anticancer pharmaceuticals - questions and answers
16 May 2018 EMA/CHMP/ICH/453684/2016 Committee for Human Medicinal Products ICH S9 guideline on nonclinical evaluation for anticancer pharmaceuticals - questions and answers Step 5 Transmission to CHMP
More informationS9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers
S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers Current Step 4 version International Council for Harmonisation of Technical
More informationAmes Data Submissions and Other Qualification Data for Impurities in Drug Substances
Ames Data Submissions and Other Qualification Data for Impurities in Drug Substances Mark W. Powley, Ph.D. Pharmacologist FDA/CDER/Office of New Drugs Outline Regulatory Background Ames Assay ICH M7 Submission
More informationBMS MIST strategy and experience
BMS MIST strategy and experience DV DMDG Rozman Symposium 13 June 2017 Griff Humphreys Bristol Myers Squibb R&D Princeton, J 1 utline Intro BMS strategy to meet MIST Experiences and learnings How well
More informationRegulatory Framework for Gene Therapies Incorpora:ng Human Genome Edi:ng
Regulatory Framework for Gene Therapies Incorpora:ng Human Genome Edi:ng Anna Kwilas, Ph.D. CMC Reviewer, Gene Therapy Branch Division of Cellular and Gene Therapies Office of Tissues and Advanced Therapies
More informationNon-clinical Assessment Requirements
Non-clinical Assessment Requirements Presented by: Maria Nieto-Gutierrez Safety and Efficacy of Medicines/Human Medicines Development and Evaluation An agency of the European Union Contents: Relevance
More informationBasic principles of the safety assessment of drugs
Basic principles of the safety assessment of drugs SFT Annual meeting 2013 Björn Dahl, PhD Senior Project Director Global Safety Assessment AstraZeneca R&D Outline of presentation Safety assessment in
More informationRegulatory Science Approaches to Improve Transla8on of Nanomedicines
anomedicine and regulatory environment for nano-inves5ga5onal medicinal products. Regulatory Science Approaches to Improve Transla8on of anomedicines Beatriz Silva Lima imed UL, Faculty of Pharmacy Universidade
More informationApplying ICH M7 and ICH S9 in Drug Safety
Applying ICH M7 and ICH S9 in Drug Safety Chris Sheth Division of Hematology Oncology Toxicology Office of Hematology and Oncology Products FDA/CDER/OND Overview www.fda.gov 2 ICH S9 Nonclinical studies
More informationCurrent Guidelines for Drug-drug Interaction Evaluation
Current Guidelines for Drug-drug Interaction Evaluation Odette A Fahmi, PhD DDI-Edge Consulting, LLC June 2018 21 ST International Conference on Drug-Drug Interactions OUTLINE Recommended DDI approaches
More informationRe: Docket No. FDA-2009-D-0006 S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org April 20, 2009 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationICH S9 -Nonclinical Evaluation for Anticancer Pharmaceuticals: Questions and Answers
ICH S9 -Nonclinical Evaluation for Anticancer Pharmaceuticals: Questions and Answers May 2018 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 Legal
More informationPharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.
Pharmacology Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. 1 PHARMACODYNAMIC STUDIES A. Primary pharmacodynamics primary action in target
More informationFrom the Chain Bridge to other Bridges of the Pharmaceu7cal World Biowaiver Applica7ons in the European Scenario
Bioequivalence, Dissolu0on, Biosimilarity From the Chain Bridge to other Bridges of the Pharmaceu7cal World Biowaiver Applica7ons in the European Scenario Antalya, Turkiye, 24 April, 12015 1 Outline Guidelines
More informationImpurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA
Overview of exploratory INDs Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA July, 15 16, 2008 David Jacobson-Kram, Ph.D. DABT Office of New Drugs Center for Drug Evaluation
More informationS9 Nonclinical Evaluation for Anticancer Pharmaceuticals
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create
More informationConducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development
Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development 2015 AAPS Annual Meeting and Exposition October 28, 2015 Kimberly Raines, Ph.D. Lead Pharmacologist Quality
More informationGlobal Development Challenges: Classical and Advanced Therapy Medicinal products
Global Development Challenges: Classical and Advanced Therapy Medicinal products Beatriz Silva Lima imed, Lisbon University and Infarmed,, Portugal CHMP, CAT, SAWP Member and SWP Chair NONCLINICAL STUDIES
More informationOncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory Challenges
The content of this presentation reflects the opinion of the speaker and does not necessarily represent the official position of CDER Oncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory
More informationInternational Council for Harmonisation (ICH) Safety Guideline Updates
International Council for Harmonisation (ICH) Safety Guideline Updates ICH Regional Public Meeting Canada-U.S. Regulatory Cooperation Council November 12, 2015 Alisa Vespa, Ph.D. Health Canada Active ICH
More informationDrug Impurities: The Good, Bad and Ugly
Drug Impurities: The Good, Bad and Ugly Joel Bercu, PhD, DABT, MPH Associate Director, Environmental and Occupational Toxicology Gilead Sciences jbercu@gilead.com Medicines Impurities 2015-2016 GrimsrudBerkowitz
More informationMetabolite ID. Introduction
Metabolite ID Introduction Drug metabolism plays an increasingly important role in the drug discovery and development process. For the early discovery phase, investigating drug metabolism is intended to
More informationAccelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective
Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective Imran M. Khan, Ph.D. Division of Psychiatry Center for Drug Evaluation and Research FDA
More informationIntroduc)on to Pharmacology and Pharmacogenomics. Roxana Daneshjou May 9, 2013
Introduc)on to Pharmacology and Pharmacogenomics Roxana Daneshjou May 9, 2013 Pharmacogenomics Pharma = Drug Genomics/Gene)cs = study of gene)c informa)on Pharmacogenomics = study of how gene)cs/ genomics
More informationCenter for Drug Evaluation and Research (CDER) Perspective
Center for Drug Evaluation and Research (CDER) Perspective National Center for Toxicological Research (NCTR) Scientific Advisory Board Tim McGovern, PhD Associate Director, Pharmacology/Toxicology Office
More informationS9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers
S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers Current version dated 8 June 2016 International Council for Harmonisation of
More informationFrom Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager
From Discovery to Development of new Drugs. and pitfalls along the way by Kim Dekermendjian, PhD in Medicine BD & Key Account manager The roots of Drug Discovery Before 20 th century the term didn't exists,
More informationCytochrome P450 Genotype Panel
DOB: Age: Gender: Visit Number (FIN): Patient Results Client: Physician: ARUP Test Code: 2013098 Collection Date: 11/29/2016 Received in lab: 11/30/2016 Completion Date: 12/07/2016 Gene Genotype Phenotype
More informationRevidierte ICH M3 Auswirkungen auf die präklinische Arzneimittelentwicklung. Pharmakologie, ADME, Missbrauchs- Potential und Kombinations-Toxizität
Revidierte ICH M3 Auswirkungen auf die präklinische Arzneimittelentwicklung Pharmakologie, ADME, Missbrauchs- Potential und Kombinations-Toxizität PD Dr. Elke Röhrdanz Präklinik Fachgebiet Klinische Prüfung
More informationPRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016
PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016 1 FROM DISCOVERY TO COMMERCIALIZATION At least 10 years on average Average spend of $1.4B Less than 12% of drugs entering Phase I are approved
More informationCombining Large Animal IND Enabling Toxicology and CV Sph Studies- PRO
Safety Pharmacology Endpoints: Integration into Toxicology Studies Combining Large Animal IND Enabling Toxicology and CV Sph Studies- PRO Marc Bailie DVM, PhD Director In Vivo Facility Michigan State University,
More informationMicrodose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations Guidance for Industry
Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationDelivering on the Promise of RNA- Based Therapeu;cs
Delivering on the Promise of RNA- Based Therapeu;cs Parent Project Muscular Dystrophy Webinar June 20, 2011 Forward- Looking Statements This presenta,on includes forward- looking statements, including
More information21st Annual International Conference on Drug-Drug Interactions. Zach Mitts Northwest Account Manager
21st Annual International Conference on Drug-Drug Interactions Zach Mitts Northwest Account Manager How memorable can a 5-minute presentation be? COMPANY HISTORY From the work of our Founder, Dr. Andrew
More informationCombination Drug Applications: Nonclinical Reviewer Perspectives. Jessica J. Hawes, Ph.D.
Combination Drug Applications: Nonclinical Reviewer Perspectives Jessica J. Hawes, Ph.D. Disclaimer The opinions expressed in this presentation are solely my own and do not reflect those of the FDA, nor
More informationPreclinical studies needed in the development of human pharmaceutical drugs role of toxicology and risk assessment
Preclinical studies needed in the development of human pharmaceutical drugs role of toxicology and risk assessment Hubert Dirven Lead Validation Unit - NPI Amersham Health (GE Healthcare), Oslo Preclinical
More informationHow discovery activities can influence metabolic profiling in the regulatory space? C. DELATOUR EBF, 25 th September 2015
How discovery activities can influence metabolic profiling in the regulatory space? C. DELATOUR EBF, 25 th September 2015 Outline 2 ן Background - Objectives - Shift in Workflow - Metabolite in safety
More informationADME : OVERVIEW AND CURRENT TOPICS COPYRIGHTED MATERIAL
PART A ADME : OVERVIEW AND CURRENT TOPICS COPYRIGHTED MATERIAL 1 REGULATORY DRUG DISPOSITION AND NDA PACKAGE INCLUDING MIST Sekhar Surapaneni 1.1 INTRODUCTION Drug metabolism and pharmacokinetics (DMPK)
More information06/03/2009. Overview. Preclinical Support for Exploratory Phase I Clinical Trials. Micro-dosing IND. Pharmacological Active Single Dose IND
Preclinical Support for Exploratory Phase I Clinical Trials Clive Joseph, DSRD Sandwich Overview Identify the most appropriate development paradigm - traditional vs alternative IND approach Confidence
More informationPreclinical Development of Biologics: Case-by-case, so get off of my case!
Preclinical Development of Biologics: Case-by-case, so get off of my case! Northeast Chapter SOT David Jacobson-Kram, Ph.D., DABT Office of New Drugs Center for Drug Evaluation and Research FDA October
More informationApplied Biosystems/MDS Sciex LC/MS Users Meeting Daiichi Pure Chemicals Co., Ltd.
Introduction ADMET screening Drug-drug interaction Introduction ADMET screening 40% ADMET screening in vitro Absorption : Caco-2 Permeability, Transporter assay Distribution : Protein binding, Transporter
More informationCurrent practices on metabolite profiling and quantification in Drug Development at Boehringer-Ingelheim
Current practices on metabolite profiling and quantification in Drug Development at Boehringer-Ingelheim S Blech EBF Focus Workshop: Metabolite Profiling and Quantification Strategies in Drug R&D Sep 25,
More informationMAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT
MAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT PharmaSUG Single Day Event Using Standards, Even for Non-Standard
More informationPreclinical safety testing of diagnostic and therapeutic radiopharmaceuticals - regulatory requirements
ESSR 14: 17th European Symposium on Radiopharmacy and Radiopharmaceuticals Pamplona, 25 April 2014 Preclinical safety testing of diagnostic and therapeutic radiopharmaceuticals - regulatory requirements
More informationWhat can be done from regulatory side?
Federal Agency for Medicines and Health Products (FAMHP) What can be done from regulatory side? 9th Annual ecopa Workshop November 29-30, 2008, Brussels Dr. Sonja BEKEN Non-Clinical Assessor, Registration
More informationFirst-in-human clinical trials Behind the scenes
First-in-human clinical trials Behind the scenes Dr Douglas Francis BVSc MVSc PhD, UK/European registered toxicologist Principal Regulatory Toxicologist Prior to review by Bellberry Ethics Committee Identify
More informationGuideline on the non-clinical requirements for radiopharmaceuticals
1 2 3 15 November 2018 EMA/CHMP/SWP/686140/2018 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Draft Draft agreed by Safety Working Party October 2018 Adopted by CHMP for release for consultation
More information3Rs in Safety Testing of Human and Veterinary Pharmaceuticals
3Rs in Safety Testing of Human and Veterinary Pharmaceuticals Brussels, December 2016 Presented by Jan Willem van der Laan) Chair Safety Working Party (human) European Medicines Agency (also on behalf
More informationRegulatory compliance in Non-Clinical development
Regulatory compliance in Non-Clinical development SME Workshop Presented by Milton Bonelli on 3 October 2016 Clinical Pharmacology and Non-Clinical Office - Human Medicines R & D Support Division An agency
More informationCombination Drugs: Regulatory Guidance and Expectations
Combination Drugs: Regulatory Guidance and Expectations Philip Gatti, Ph.D. Pharmacologist/CDER Division of Cardiovascular and Renal Products CDER/FDA May 16, 2017 Disclaimer This presentation reflects
More information2017 AAM CMC Workshop
2017 AAM CMC Workshop SETTING PROPER IMPURITIES LIMITS - INCLUDING GENOTOXIC IMPURITIES INDUSTRY PERSPECTIVE Janet Vaughn, Sr. Director Regulatory Affairs Teva Pharmaceuticals USA 23 May, 2017 Disclaimer
More informationGuidance for Industry
Guidance for Industry M4S: The CTD Safety U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research
More informationOverview Everything You Wanted to Know About GLPs. but were afraid to ask
Overview Everything You Wanted to Know About GLPs. but were afraid to ask Janet Rose Christensen, M.S.P.H. Vice President, Regulatory Affairs and Quality AVI BioPharma, Inc. Portland, OR jrc@avibio.com/503.227.00554
More informationStructure and content of an IMPD. What is required for first into man trial?
What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation
More informationDetection of toxicity to reproduction for human pharmaceuticals. Explanatory slides agreed by EWG members
Detection of toxicity to reproduction for human pharmaceuticals Explanatory slides agreed by EWG members 2 October 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals
More informationINTRODUCTION TO PHARMACOLOGY
INTRODUCTION TO PHARMACOLOGY Pharmacology is the study of how chemicals interact with the body Endogenous hormones, growth factors, etc Exogenous drugs Two areas of study Pharmacodynamics Interaction of
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS
European Medicines Agency London, 24 January 2008 Doc. Ref. EMEA/CHMP/SWP/258498/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS
More informationInternational Consortium For Innovation & Quality in Pharmaceutical Development
International Consortium For Innovation & Quality in Pharmaceutical Development s on Draft Guidance: FDA Draft Guidance: Investigational Enzyme Replacement Therapy Products: Nonclinical Assessment (draft
More informationSkills Required by Pharmacologists and Physiologists in Today s Pharmaceu:cal Industry
Skills Required by Pharmacologists and Physiologists in Today s Pharmaceu:cal Industry Iok- Hou Pang, PhD Pharmaceutical Sciences!! University of North Texas Health Science Center! Outline of Presenta:on
More informationValue Scale (1-5) 1 I. Final Product Profile Characteristics of the product required for patient care
In this example, the majority of the compounds was active in the xenograft model and showed "drug-like" properties from in-silico and experimental data. However, the animal studies showed moderate toxicity
More informationValue Scale (1-5) Summary of Results
In this example, the set of compounds that were studied satisfied many of the criteria for "drug likeness". However, in this program, there were issues with potency, novelty, and metabolic stability. This
More informationFrom Drug Discovery to IND Saving Time and Money Through Smart Study Design
From Drug Discovery to IND Saving Time and Money Through Smart Study Design Stephen Madden BSc PhD CBiol FSB Head, Metabolism and Pharmacokinetics Charles River Preclinical Services, Edinburgh Outline
More informationComparative Study of Regulatory Requirements for Biologics Filing in United States and European Union
Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union Mr. Shashi Kumar Yadav Assistant Professor Sri Indu Institute of Pharmacy Hyderabad Outline Introduction
More informationToxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development
Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development No. 1 of 10 1. regulates all the drugs products manufactured and sold in the USA. (A) EMEA (B) IND (C) FDA (D) NDA (E) OSHA
More informationWorkshop: Applying Exposure Science to Increase the Utility of Non-Animal Data in Efficacy and Safety Testing, 16 Feb. 2017
Workshop: Applying Exposure Science to Increase the Utility of Non-Animal Data in Efficacy and Safety Testing, 16 Feb. 2017 Presentation Outline Should we account for kinetics in vitro and in vivo for
More informationInstitute of Pharmaceutical Technology and Biopharmacy University of Pécs szeptember 22. 1
Institute of Pharmaceutical Technology and Biopharmacy University of Pécs 2017. szeptember 22. 1 Pre-discovery Goal: Understand the disease and choose a target molecule. How: Scientists in pharmaceutical
More informationIntroduction to Drug Design and Discovery
Introduction to Drug Design and Discovery Course: Drug Design Course code: 0510412 Dr. Balakumar Chandrasekaran Dr. Bilal Al-Jaidi Assistant Professors, Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy,
More informationNMR in Drug Metabolism Extraction NMR - Keeping up with the Pace of Drug Discovery. Dr Ute Gerhard
F NMR in Drug Metabolism Extraction NMR - Keeping up with the Pace of Drug Discovery Dr Ute Gerhard The Early Days Eat plant Feel Worse Feel Better Try again Drug! The Golden Age Make molecule Feed to
More informationPredicting Metabolites
Predicting Metabolites Enhancing An Expert System With Machine Learning Chris Barber Director f Science chris.barber@lhasalimited.org Boston, May 2015 Lhasa Limited: What We Do Lhasa Limited is a not-for-profit
More informationRe: Docket No. FDA-2015-D-1246: Draft Guidance on Investigational Enzyme Replacement Therapy Products: Nonclinical Assessment
July 13, 2015 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2015-D-1246: Draft Guidance on Investigational Enzyme Replacement
More informationPredicting Metabolites
Predicting Metabolites Enhancing An Expert System With Machine Learning Chris Barber Director f Science chris.barber@lhasalimited.org Boston, May 2015 Lhasa Limited: What We Do Lhasa Limited is a not-for-profit
More informationMAINTENANCE OF THE ICH GUIDELINE ON NON-CLINICAL SAFETY STUDIES FOR THE CONDUCT OF HUMAN CLINICAL TRIALS FOR PHARMACEUTICALS M3(R1)
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE MAINTENANCE OF THE ICH GUIDELINE ON NON-CLINICAL
More informationBiosimilar Monoclonal Antibodies: Registration Requirements. Henry M. J. Leng
Biosimilar Monoclonal Antibodies: Registration Requirements Henry M. J. Leng Disclaimer This presentation is given in my personal capacity and represents only the author s personal views and does not represent
More informationLaura Andrews, PhD, DABT, Fellow ATS
Laura Andrews, PhD, DABT, Fellow ATS What is a Biologic? From PHS Act of 1944 A biologic is any virus, toxin, antitoxin, therapeutic serum, vaccine, blood, blood component or derivative, allergenic products
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) POSITION PAPER ON NON-CLINICAL SAFETY STUDIES TO SUPPORT CLINICAL TRIALS WITH A SINGLE MICRODOSE
European Medicines Agency Evaluation of Medicines for Human Use London, 23 June 2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) POSITION PAPER ON NON-CLINICAL SAFETY STUDIES TO SUPPORT CLINICAL
More informationUse of (Q)SAR to Evaluate Potential Genotoxic Impurities
Use of (Q)SAR to Evaluate Potential Genotoxic Impurities Naomi Kruhlak, PhD Lead, Chemical Informatics Program Division of Applied Regulatory Science Office of Clinical Pharmacology Office of Translational
More informationUpdate on DDI Guidance of the FDA - In Vitro
Update on DDI Guidance of the FDA - In Vitro Xinning Yang, Ph.D. Policy lead Guidance & Policy Team (GPT) Office of Clinical Pharmacology (OCP) Office of Translational Sciences (OTS) Center for Drug Evaluation
More informationJMP Clinical 4.0 adds Ways to Explore Clinical Trials Data Visually
JMP Clinical 4.0 adds Ways to Explore Clinical Trials Data Visually Dr. Valerie Nedbal JMP Pharmaceu4cal Technical Manager SAS Ins4tute Copyright 2010 SAS Institute Inc. All rights reserved. JMP Clinical
More informationToxicological Qualification of Impurities. Klaus Olejniczak, Non-clinical Regulatory Consultant, Berlin
Toxicological Qualification of Impurities Klaus Olejniczak, Non-clinical Regulatory Consultant, Berlin klausolejniczak@yahoo.de Assessment of Impurities Relevant Information Impurities in new substances
More informationFood Safety By Design Focus on FSMA Preven<ve Controls. Presented by: Dr. David Acheson
Food Safety By Design Focus on FSMA Preven
More informationHuman ips/es Cell Technology and Its Applica;on to Toxicology Tes;ng
Human ips/es Cell Technology and Its Applica;on to Toxicology Tes;ng - Especially focusing on in vitro cardiac func;on toxicity- Atsushi Sanbuissho (Daiichi Sankyo Co. Ltd.) Kenji Yasuda (Tokyo Medical
More informationThe TetraQ Difference. Quality Preclinical Drug Development Solutions. Provide advice and tailored solutions, not just a menu of choices
A leading Australian contract research organisation (CRO) providing integrated preclinical drug development services to the biotech and pharmaceutical industries The TetraQ Difference Located at The University
More informationComments and suggestions from reviewer
Comments and suggestions from reviewer Page 1 of 13 Title: WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology: WHO/rDNA_DRAFT/12
More informationSome challenges in the development of new toxicity assays using in vitro methods
1 Some challenges in the development of new toxicity assays using in vitro methods J Malcolm Wilkinson, CEO, Kirkstall Ltd. Quasi Vivo - saving lives through better science The challenge: long drug development
More informationVELTIS : INNOVATIVE ALBUMIN BASED TECHNOLOGY FOR HALF- LIFE EXTENSION AND OPTIMIZATION OF BIOTHERAPEUTICS
VELTIS : INNOVATIVE ALBUMIN BASED TECHNOLOGY FOR HALF- LIFE EXTENSION AND OPTIMIZATION OF BIOTHERAPEUTICS Dr Mikael Bjerg Caspersen Industrial Biotechnology Conference August 10 th 2015 INNOVATIVE TECHNOLOGY
More informationDeputy Director General of Enterprise and Industry DG. Global Cooperation on alternatives (3Rs) to animal testing
Ref. Ares(2012)1356871-16/11/2012 SPEECH Antti PELTOMÄKI Deputy Director General of Enterprise and Industry DG Opening speech for the 8 th EPAA Annual Conference Global Cooperation on alternatives (3Rs)
More informationPhase 1 Clinical Studies First-In-Human (FIH) <Chapter 31> Pharmacologically-Guided Dose Escalation
Phase 1 Clinical Studies First-In-Human (FIH) Pharmacologically-Guided Dose Escalation Jerry M. Collins, Ph.D. Developmental Therapeutics Program Division of Cancer Treatment and Diagnosis,
More informationIntroduction to Drug Development in Commercializing Biomedical Technology
Introduction to Drug Development in Commercializing Biomedical Technology Kevin W. Hunt, Ph.D. Director of Biopharmaceutical Product Development Office of Technology Development and Head of Translational
More informationBioSafe Introduction and rare disease activities
BioSafe Introduction and rare disease activities Tim MacLachlan, PhD, DABT Chair, BioSafe Leadership Committee Executive Director, Biologics Safety Assessment Preclinical Safety, Novartis BIOTECHNOLOGY
More informationCurrent practice and future vision on metabolite profiling and quantification in Drug development
Current practice and future vision on metabolite profiling and quantification in Drug development Geert Mannens EBF Focus workshop Metabolite Profiling and Quantification Strategies in Drug R&D Sept 25,
More informationPreclinical Drug Development
Preclinical Drug Development A guidance prepared by From a 2004 NIH Summit Workshop: A major reason for the tremendous cost of drug development is the high rate of drug candidate failure during clinical
More informationCYP IMMUNOINHIBIT KIT PRODUCT# Hu-A011A, Hu-A011B
CYP IMMUNOINHIBIT KIT PRODUCT# Hu-A011A, Hu-A011B Please visit our website at: http://cyp450-gp.com to confirm that you have the most current version of this manual. Contact CYP450-GP sales (sales@cyp450-gp.com)
More informationRegulatory Updates in Clinical Pharmacology, Nonclinical Development, and Translational Medicine
Regulatory Updates in Clinical Pharmacology, Nonclinical Development, and Translational Medicine Luana Pesco Koplowitz, MD, PhD, FCP, FFPM President and Chief Medical & Scientific Officer DUCK FLATS Pharma,
More informationGuideline for the quality, safety and efficacy of follow-on biological medicinal products
Guideline for the quality, safety and efficacy of follow-on biological medicinal products 1. Introduction A follow-on biological medicinal product (hereinafter referred to as FOBMP) is considered as a
More informationFDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer
FDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer Yongjie Zhou, M.D., Ph.D. FDA/CBER/OCTGT/DCEPT Yongjie.zhou@fda.hhs.gov isbtc Global Regulatory Summit October 29, 2008
More informationBeth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group
ICH Considerations on General Principles to Address the Risk of Inadvertent Germline Integration of Gene Therapy Vectors and Current Topics on Gene Therapy in USA Beth Hutchins, PhD PhRMA ICH Gene Therapy
More information2015 Detroit R & D Product Catalog
2727 Second Ave. Suite 4113 Detroit, MI 48201 Phone: (313) 961-1606; Fax: (313)963-7130 Email: info@detroitrandd.com Web: www.detroitrandd.com ELISA Kits 2015 Detroit R & D Product Catalog www.detroitrandd.com
More informationThe Exploratory IND (Phase 0) Concept
The Exploratory IND (Phase 0) Concept Joseph C. Hung Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA In recent years, the costs for drug research and development (R&D) have escalated despite
More informationPHARMATRAIN BASE COURSE MODULE 2: NON-CLINICAL, PHARMACEUTICAL AND EARLY CLINICAL DEVELOPMENT LEARNING OUTCOMES
CEMDC, Module 2 Website: http://cemdc.eu November 19 th -22 nd, 2015. Place: Ljubljana, Slovenia Address: University of Ljubljana, Faculty of Pharmacy, ASKERCEVA 7, 1000 Ljubljana Module Leaders: Prof.
More informationGene Regulatory Networks Computa.onal Genomics Seyoung Kim
Gene Regulatory Networks 02-710 Computa.onal Genomics Seyoung Kim Transcrip6on Factor Binding Transcrip6on Control Gene transcrip.on is influenced by Transcrip.on factor binding affinity for the regulatory
More information